Synthetic glycans control gut microbiome structure and mitigate colitis in mice.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
10 03 2022
Historique:
received: 24 08 2021
accepted: 08 02 2022
entrez: 11 3 2022
pubmed: 12 3 2022
medline: 6 4 2022
Statut: epublish

Résumé

Relative abundances of bacterial species in the gut microbiome have been linked to many diseases. Species of gut bacteria are ecologically differentiated by their abilities to metabolize different glycans, making glycan delivery a powerful way to alter the microbiome to promote health. Here, we study the properties and therapeutic potential of chemically diverse synthetic glycans (SGs). Fermentation of SGs by gut microbiome cultures results in compound-specific shifts in taxonomic and metabolite profiles not observed with reference glycans, including prebiotics. Model enteric pathogens grow poorly on most SGs, potentially increasing their safety for at-risk populations. SGs increase survival, reduce weight loss, and improve clinical scores in mouse models of colitis. Synthetic glycans are thus a promising modality to improve health through selective changes to the gut microbiome.

Identifiants

pubmed: 35273143
doi: 10.1038/s41467-022-28856-x
pii: 10.1038/s41467-022-28856-x
pmc: PMC8913648
doi:

Substances chimiques

Polysaccharides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1244

Subventions

Organisme : NIDDK NIH HHS
ID : P30 DK098722
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Vatanen, T. et al. Variation in microbiome LPS immunogenicity contributes to autoimmunity in humans. Cell 165, 842–853 (2016).
pubmed: 27133167 pmcid: 4950857 doi: 10.1016/j.cell.2016.04.007
Duscha, A. et al. Propionic acid shapes the multiple sclerosis disease course by an immunomodulatory mechanism. Cell 180, 1067–1080.e16 (2020).
pubmed: 32160527 doi: 10.1016/j.cell.2020.02.035
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018).
pubmed: 29097494 doi: 10.1126/science.aan3706
Dabke, K., Hendrick, G. & Devkota, S. The gut microbiome and metabolic syndrome. J. Clin. Invest. 129, 4050–4057 (2019).
pubmed: 31573550 pmcid: 6763239 doi: 10.1172/JCI129194
Bajaj, J. S. The role of microbiota in hepatic encephalopathy. Gut Microbes 5, 397–403 (2014).
pubmed: 24690956 pmcid: 4153779 doi: 10.4161/gmic.28684
Taroncher-Oldenburg, G. et al. Translating microbiome futures. Nat. Biotechnol. 36, 1037–1042 (2018).
pubmed: 30412201 doi: 10.1038/nbt.4287
Patnode, M. L. et al. Interspecies competition impacts targeted manipulation of human gut bacteria by fiber-derived glycans. Cell 179, 59–73.e13 (2019).
pubmed: 31539500 pmcid: 6760872 doi: 10.1016/j.cell.2019.08.011
Martens, E. C. et al. Recognition and degradation of plant cell wall polysaccharides by two human gut symbionts. PLoS Biol. 9, e1001221 (2011).
pubmed: 22205877 pmcid: 3243724 doi: 10.1371/journal.pbio.1001221
Baxter, N. T. et al. Dynamics of human gut microbiota and short-chain fatty acids in response to dietary interventions with three fermentable fibers. MBio https://doi.org/10.1128/mBio.02566-18 (2019).
Zhao, L. et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science 359, 1151–1156 (2018).
pubmed: 29590046 doi: 10.1126/science.aao5774
Menni, C. et al. Gut microbiome diversity and high-fibre intake are related to lower long-term weight gain. Int. J. Obes. 2005 41, 1099–1105 (2017).
O’Keefe, S. J. D. et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat. Commun. 6, 6342 (2015).
pubmed: 25919227 doi: 10.1038/ncomms7342
Holscher, H. D. et al. Effects of prebiotic-containing infant formula on gastrointestinal tolerance and fecal microbiota in a randomized controlled trial. JPEN J. Parenter. Enter. Nutr. 36, 95S–105S (2012).
doi: 10.1177/0148607111430087
Walton, G. E. et al. A randomised crossover study investigating the effects of galacto-oligosaccharides on the faecal microbiota in men and women over 50 years of age. Br. J. Nutr. 107, 1466–1475 (2012).
pubmed: 21910949 doi: 10.1017/S0007114511004697
Lecerf, J.-M. et al. Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br. J. Nutr. 108, 1847–1858 (2012).
pubmed: 22264499 doi: 10.1017/S0007114511007252
Hong, L. et al. Pullulan nanoparticles as prebiotics enhance the antibacterial p[roperties of Lactobacillus plantarum through the induction of mild stress in probiotics. Front. Microbiol. 10, 142 (2019).
pubmed: 30787918 pmcid: 6372531 doi: 10.3389/fmicb.2019.00142
Ballongue, J., Schumann, C. & Quignon, P. Effects of lactulose and lactitol on colonic microflora and enzymatic activity. Scand. J. Gastroenterol. Suppl. 222, 41–44 (1997).
pubmed: 9145445 doi: 10.1080/00365521.1997.11720716
Von Maltzahn, G., Silverman, J., Yamanaka, Y., Milwid, J. & Geremia, J. Glycan therapeutics and related methods thereof. US Patent 10,314,853 (2019).
Geremia, J., Liu, C. & Murphy, A. Methods of producing glycan polymers. US Patent app 16/761115 (2020).
Hansen, C. H. F. et al. Targeting gut microbiota and barrier function with prebiotics to alleviate autoimmune manifestations in NOD mice. Diabetologia 62, 1689–1700 (2019).
pubmed: 31139852 doi: 10.1007/s00125-019-4910-5
Lewis, S., Burmeister, S. & Brazier, J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin. Gastroenterol. Hepatol.3, 442–448 (2005).
pubmed: 15880313 doi: 10.1016/S1542-3565(04)00677-9
Whelan, K. et al. Fructooligosaccharides and fiber partially prevent the alterations in fecal microbiota and short-chain fatty acid concentrations caused by standard enteral formula in healthy humans. J. Nutr. 135, 1896–1902 (2005).
pubmed: 16046714 doi: 10.1093/jn/135.8.1896
Litvak, Y., Byndloss, M. X. & Bäumler, A. J. Colonocyte metabolism shapes the gut microbiota. Science 362, eaat9076 (2018).
Berggren, A. M., Nyman, E. M., Lundquist, I. & Björck, I. M. Influence of orally and rectally administered propionate on cholesterol and glucose metabolism in obese rats. Br. J. Nutr. 76, 287–294 (1996).
pubmed: 8813902 doi: 10.1079/BJN19960032
El Hage, R., Hernandez-Sanabria, E., Calatayud Arroyo, M., Props, R. & Van de Wiele, T. Propionate-producing consortium restores antibiotic-induced dysbiosis in a dynamic in vitro model of the human intestinal microbial ecosystem. Front. Microbiol. 10, 1206 (2019).
Smith, P. M. et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341, 569–573 (2013).
pubmed: 23828891 doi: 10.1126/science.1241165
Arpaia, N. et al. Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504, 451–455 (2013).
pubmed: 24226773 pmcid: 3869884 doi: 10.1038/nature12726
Darwin, W. C. & Cord-Ruwisch, R. Concurrent lactic and volatile fatty acid analysis of microbial fermentation samples by gas chromatography with heat pre-treatment. J. Chromatogr. Sci. 56, 1–5 (2018).
pubmed: 29069353 doi: 10.1093/chromsci/bmx086
Seo, A. Y., Kim, N. & Oh, D. H. Abdominal bloating: pathophysiology and treatment. J. Neurogastroenterol. Motil. 19, 433–453 (2013).
pubmed: 24199004 pmcid: 3816178 doi: 10.5056/jnm.2013.19.4.433
Azpiroz, F. Intestinal gas dynamics: mechanisms and clinical relevance. Gut 54, 893–895 (2005).
pubmed: 15951528 pmcid: 1774596 doi: 10.1136/gut.2004.048868
Takahashi, K. et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion 93, 59–65 (2016).
pubmed: 26789999 doi: 10.1159/000441768
Takeshita, K. et al. A single species of clostridium subcluster XIVa decreased in ulcerative colitis patients. Inflamm. Bowel Dis. 22, 2802–2810 (2016).
pubmed: 27824645 doi: 10.1097/MIB.0000000000000972
Cruz, P. D. et al. Association between specific mucosa-associated microbiota in Crohn’s disease at the time of resection and subsequent disease recurrence: A pilot study. J. Gastroenterol. Hepatol. 30, 268–278 (2015).
pubmed: 25087692 doi: 10.1111/jgh.12694
Meyer, D. & Stasse-Wolthuis, M. The bifidogenic effect of inulin and oligofructose and its consequences for gut health. Eur. J. Clin. Nutr. 63, 1277–1289 (2009).
pubmed: 19690573 doi: 10.1038/ejcn.2009.64
Stoma, I. et al. Compositional flux within the intestinal microbiota and risk for bloodstream infection with gram-negative bacteria. Clin. Infect. Dis. 73, e4627–e4635 (2020).
pmcid: 8662789 doi: 10.1093/cid/ciaa068
Liss, B. J. et al. Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40, 613–619 (2012).
pubmed: 22665143 doi: 10.1007/s15010-012-0269-y
Dubin, K. & Pamer, E. G. Enterococci and their interactions with the intestinal microbiome. Microbiol. Spectr. https://doi.org/10.1128/microbiolspec.BAD-0014-2016 (2014).
Hallmann, F. Toxicity of commonly used laxatives. Med. Sci. Monit. 6, 618–628 (2000).
pubmed: 11208382
Morgan, M. Y. Current state of knowledge of hepatic encephalopathy (part III): non-absorbable disaccharides. Metab. Brain Dis. 31, 1361–1364 (2016).
pubmed: 27638474 pmcid: 5145904 doi: 10.1007/s11011-016-9910-2
Boutard, M. et al. Functional diversity of carbohydrate-active enzymes enabling a bacterium to ferment plant biomass. PLoS Genet. 10, e1004773 (2014).
pubmed: 25393313 pmcid: 4230839 doi: 10.1371/journal.pgen.1004773
Lombard, V., Golaconda Ramulu, H., Drula, E., Coutinho, P. M. & Henrissat, B. The carbohydrate-active enzymes database (CAZy) in 2013. Nucleic Acids Res. 42, D490–D495 (2014).
pubmed: 24270786 doi: 10.1093/nar/gkt1178
Salyers, A. A., West, S. E., Vercellotti, J. R. & Wilkins, T. D. Fermentation of mucins and plant polysaccharides by anaerobic bacteria from the human colon. Appl. Environ. Microbiol. 34, 529–533 (1977).
pubmed: 563214 pmcid: 242695 doi: 10.1128/aem.34.5.529-533.1977
Koropatkin, N. M., Cameron, E. A. & Martens, E. C. How glycan metabolism shapes the human gut microbiota. Nat. Rev. Microbiol. 10, 323–335 (2012).
pubmed: 22491358 pmcid: 4005082 doi: 10.1038/nrmicro2746
Di Lauro, B. et al. Isolation and characterization of a new family 42 β-galactosidase from the thermoacidophilic bacterium Alicyclobacillus acidocaldarius: Identification of the active site residues. Biochim. Biophys. Acta 1784, 292–301 (2008).
pubmed: 18068682 doi: 10.1016/j.bbapap.2007.10.013
Milani, C. et al. Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut. Sci. Rep. 5, 15782 (2015).
pubmed: 26506949 pmcid: 4623478 doi: 10.1038/srep15782
Rietschel-Berst, M. et al. Extracellular exo-beta-galactofuranosidase from Penicillium charlesii: isolation, purification, and properties. J. Biol. Chem. 252, 3219–3226 (1977).
pubmed: 863879 doi: 10.1016/S0021-9258(17)40374-7
Sokol, H. et al. Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn’s disease. Gut 69, 462–472 (2020).
pubmed: 31142586 doi: 10.1136/gutjnl-2019-318719
Wang, T. et al. Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J. 6, 320–329 (2012).
pubmed: 21850056 doi: 10.1038/ismej.2011.109
Crobach, M. J. T. et al. The bacterial gut microbiota of adult patients infected, colonized or noncolonized by Clostridioides difficile. Microorganisms 8, 677 (2020).
Mullish, B. H. et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridioides difficile infection. Gut 68, 1791–1800 (2019).
pubmed: 30816855 doi: 10.1136/gutjnl-2018-317842
Wang, K. et al. Parabacteroides distasonis alleviates obesity and metabolic dysfunctions via production of succinate and secondary bile acids. Cell Rep. 26, 222–235.e5 (2019).
pubmed: 30605678 doi: 10.1016/j.celrep.2018.12.028
Kottler, R. et al. Development of a high-throughput glycoanalysis method for the characterization of oligosaccharides in human milk utilizing multiplexed capillary gel electrophoresis with laser-induced fluorescence detection. Electrophoresis 34, 2323–2336 (2013).
pubmed: 23716415 doi: 10.1002/elps.201300016
Hennig, R. et al. Towards personalized diagnostics via longitudinal study of the human plasma N-glycome. Biochim. Biophys. Acta 1860, 1728–1738 (2016).
pubmed: 27038647 doi: 10.1016/j.bbagen.2016.03.035
Hakomori, S. A rapid permethylation of glycolipid, and polysaccharide catalyzed by methylsulfinyl carbanion in dimethyl sulfoxide. J. Biochem. (Tokyo) 55, 205–208 (1964).
Rovalino-Córdova, A. M., Fogliano, V. & Capuano, E. Effect of bean structure on microbiota utilization of plant nutrients: An in-vitro study using the simulator of the human intestinal microbial ecosystem (SHIME®). J. Funct. Foods 73, 104087 (2020).
doi: 10.1016/j.jff.2020.104087
Heux, S., Philippe, B. & Portais, J.-C. High-throughput workflow for monitoring and mining bioprocess data and its application to inferring the physiological response of Escherichia coli to perturbations. Appl. Environ. Microbiol. 77, 7040–7049 (2011).
pubmed: 21841033 pmcid: 3187081 doi: 10.1128/AEM.05838-11
Bayne, C. phgrofit R package (version 1.0.2). https://doi.org/10.5281/zenodo.5948925 (2022).
Edgar, R. C. UNOISE2: improved error-correction for Illumina 16S and ITS amplicon sequencing. bioRxiv https://doi.org/10.1101/081257 (2016).
Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods 13, 581–583 (2016).
pubmed: 27214047 pmcid: 4927377 doi: 10.1038/nmeth.3869
Hillmann, B. et al. Evaluating the information content of shallow shotgun metagenomics. MSystems https://doi.org/10.1128/mSystems.00069-18 (2018).
Oksanen, J. et al. vegan: Community Ecology Package. R package (version 2.5-6). https://CRAN.R-project.org/package=vegan (2020).
Zhang, H. et al. dbCAN2: a meta server for automated carbohydrate-active enzyme annotation. Nucleic Acids Res. 46, W95–W101 (2018).
pubmed: 29771380 pmcid: 6031026 doi: 10.1093/nar/gky418
Al-Ghalith, G. & Knights, D. BURST enables mathematically optimal short-read alignment for big data. bioRxiv https://doi.org/10.1101/2020.09.08.287128 (2020).
Han, J., Lin, K., Sequeira, C. & Borchers, C. H. An isotope-labeled chemical derivatization method for the quantitation of short-chain fatty acids in human feces by liquid chromatography-tandem mass spectrometry. Anal. Chim. Acta 854, 86–94 (2015).
pubmed: 25479871 doi: 10.1016/j.aca.2014.11.015

Auteurs

Andrew C Tolonen (AC)

Kaleido Biosciences, Lexington, MA, 02421, USA. tolonen@alum.mit.edu.

Nicholas Beauchemin (N)

Kaleido Biosciences, Lexington, MA, 02421, USA.
Seres Therapeutics, Cambridge, MA, 02139, USA.

Charlie Bayne (C)

Kaleido Biosciences, Lexington, MA, 02421, USA.

Lingyao Li (L)

Kaleido Biosciences, Lexington, MA, 02421, USA.

Jie Tan (J)

Kaleido Biosciences, Lexington, MA, 02421, USA.

Jackson Lee (J)

Kaleido Biosciences, Lexington, MA, 02421, USA.

Brian M Meehan (BM)

Kaleido Biosciences, Lexington, MA, 02421, USA.
Pareto Bio, Cambridge, MA, 02140, USA.

Jeffrey Meisner (J)

Kaleido Biosciences, Lexington, MA, 02421, USA.

Yves Millet (Y)

Kaleido Biosciences, Lexington, MA, 02421, USA.

Gabrielle LeBlanc (G)

Kaleido Biosciences, Lexington, MA, 02421, USA.

Robert Kottler (R)

glyXera GmbH, 39120, Magdeburg, Germany.

Erdmann Rapp (E)

glyXera GmbH, 39120, Magdeburg, Germany.
Max Planck Institute for Dynamics of Complex Technical Systems, 39106, Magdeburg, Germany.

Chris Murphy (C)

Kaleido Biosciences, Lexington, MA, 02421, USA.
Bacainn Therapeutics, Inc and Morningside BioPharma Advisory, Concord, MA, 01742, USA.

Peter J Turnbaugh (PJ)

Department of Microbiology and Immunology, University of California San Francisco, San Francisco, CA, 94143, USA.

Geoffrey von Maltzahn (G)

Kaleido Biosciences, Lexington, MA, 02421, USA.
Flagship Pioneering, Cambridge, MA, 02142, USA.

Christopher M Liu (CM)

Kaleido Biosciences, Lexington, MA, 02421, USA.
Exo Therapeutics, Watertown, MA, 02472, USA.

Johan E T van Hylckama Vlieg (JET)

Kaleido Biosciences, Lexington, MA, 02421, USA. johan.van-hylckama-vlieg@kaleido.com.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH